Want to see NTLA full AI Analyst Report?
NTLA Stock Chart & Stats
$10.73
-$0.37(-3.33%)
At close: 4:00 PM EDT
$10.73
-$0.37(-3.33%)
Day’s Range― - ―
52-Week Range$7.95 - $28.25
Previous CloseN/A
Volume3.46M
Average Volume (3M)5.60M
Market Cap
$1.69B
Enterprise Value$1.89K
Total Cash (Recent Filing)$437.76M
Total Debt (Recent Filing)$73.41M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Nov 05, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.36
Shares Outstanding140,126,700
10 Day Avg. Volume4,326,939
30 Day Avg. Volume5,601,621
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.45
Price to Sales (P/S)14.40
P/FCF Ratio-2.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.90Price Target Upside94.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.2
Revenue Forecast (FY)$50.71M
Bulls Say, Bears Say
Bulls Say
Robust Phase III Efficacy For Lonvo‑zConvincing Phase III results establish lonvo‑z as a potential one‑time, first‑in‑class therapy for HAE. Durable high efficacy and favorable safety support payer acceptance, simplifies chronic disease management, and strengthens Intellia's clinical credibility and commercialization potential long term.
Strengthened Balance Sheet And RunwayA large cash balance and recent financing materially extend the company's runway, reducing near‑term financing risk while the company advances regulatory filings and launches. This financial cushion supports ongoing trials, commercial prepaids, and regulatory interactions over multiple quarters.
Potent Nex‑z Biology And Advancing Phase IIIStrong, consistent TTR knockdown from one‑time nex‑z dosing indicates meaningful biological differentiation versus chronic silencers. Deep target engagement and predictable durability underpin a structurally advantaged product profile and de‑risk Phase III readouts and long‑term commercial positioning.
Bears Say
Nex‑z Liver Enzyme Safety SignalA treatment‑emergent severe liver enzyme signal creates regulatory and label risk that can impose monitoring requirements, restrict indications, or demand mitigation strategies. These outcomes can raise development costs, delay approvals, and reduce post‑launch uptake versus initially projected addressable populations.
HLA C*05:01 Subgroup ComplexityAssociation with an HLA subgroup necessitates pre‑screening and may exclude or complicate treatment for a material patient subset. Routine HLA typing increases clinical and commercial complexity, may shrink the eligible market, and could hinder trial enrollment diversity and payer acceptance long term.
Weak Cash Generation And Ongoing BurnSustained negative operating and free cash flow means reliance on external financing to fund R&D and commercialization. If regulatory or launch timelines slip, the company may face dilution or constrained investments, limiting strategic flexibility and increasing execution risk over the medium term.
Intellia Therapeutics News
NTLA FAQ
What was Intellia Therapeutics Inc’s price range in the past 12 months?
Intellia Therapeutics Inc lowest stock price was $7.95 and its highest was $28.25 in the past 12 months.
What is Intellia Therapeutics Inc’s market cap?
Intellia Therapeutics Inc’s market cap is $1.69B.
When is Intellia Therapeutics Inc’s upcoming earnings report date?
Intellia Therapeutics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 77 days.
How were Intellia Therapeutics Inc’s earnings last quarter?
Intellia Therapeutics Inc released its earnings results on Aug 06, 2026. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.799 by -$0.001.
Is Intellia Therapeutics Inc overvalued?
According to Wall Street analysts Intellia Therapeutics Inc’s price is currently Undervalued.
Does Intellia Therapeutics Inc pay dividends?
Intellia Therapeutics Inc does not currently pay dividends.
What is Intellia Therapeutics Inc’s EPS estimate?
Intellia Therapeutics Inc’s EPS estimate is -0.8.
How many shares outstanding does Intellia Therapeutics Inc have?
Intellia Therapeutics Inc has 140,126,700 shares outstanding.
What happened to Intellia Therapeutics Inc’s price movement after its last earnings report?
Intellia Therapeutics Inc reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.799. Following the earnings report the stock price went up 2.461%.
Which hedge fund is a major shareholder of Intellia Therapeutics Inc?
Currently, no hedge funds are holding shares in NTLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intellia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.90 (94.78% Upside)
$20.90 (94.78% Upside)
Blogger Sentiment
Bullish
NTLA Sentiment 71%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 49.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $135.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.64%
Trailing 12-Months
Company Description
Intellia Therapeutics Inc
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
NTLA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, concrete clinical progress — most notably the unequivocal Phase III success for lonvo‑z (87% attack reduction, 62% attack‑free and therapy‑free, favorable safety) and compelling nex‑z biological data (≈90% TTR knockdown, rapid and durable) — alongside active regulatory and commercial preparations. Financially, the company strengthened its cash position with a ~$195M financing and maintains a runway into at least 2028, although collaboration revenue declined and G&A rose as commercial build‑out continues. The primary concern is a nex‑z liver enzyme safety signal and the identification of an HLA C*05:01 subgroup (~12% of samples) associated with higher Grade 3+ transaminase events; the company has implemented mitigation, added HLA typing to protocols, and is engaging regulators. Overall, the positive clinical milestones and clear mitigation plan for the safety finding outweigh the operational and financial headwinds discussed.View all NTLA earnings summariesNTLA Revenue Breakdown
100.00% Collaboration revenue
NTLA Stock 12 Month Forecast
Average Price Target
$20.90
▲(94.78% Upside)
Technical Analysis
Kura Oncology
―
Compass Therapeutics
―
AbCellera Biologics
―
Janux Therapeutics Inc
―
Bicara Therapeutics Inc.
―
Ownership Overview
1.60% Insiders
15.31% Mutual Funds
34.28% Other Institutional Investors
19.00% Public Companies and Individual Investors